Allergan Inc (AGN) 186.77 $AGN
eVivite.com Continues to Sell VIVITÉ(R) Products After Allergan Announces Its Discontinuation
PRWeb - 2 hrs 17 mins ago
After Allergan's announcement that they will be discontinuing their VIVITÉ(R) skin care product line, online supplier eVivite.com announced their plans to resume sales as long as products are available. As of March 2014 Allergen had already halted production of the products, and they informed retailers that they would only be distributing what had already been produced. The final shipments to suppliers are expected to occur sometime in June.
AGN: 186.77 (+4.17)
San Marcos Dentist, Jeffrey Allred, Certified by Allergan to Provide Botox to Patients Having Dental Problems
PRWeb - Wed Oct 29, 2:11PM CDT
Jeffrey Allred DDS at Allred Dental in San Marcos, CA is now providing therapeutic Botox injections. Botox till recently was known to be used mainly for cosmetic purposes, but now it is used in dentistry as well.
AGN: 186.77 (+4.17)
Express Scripts Reports In-Line Q3 Earnings, Narrows View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:26PM CDT
Express Scripts Holding Company posted third-quarter 2014 earnings per share (excluding special items) of $1.29, in line with the Zacks Consensus Estimate.
AGN: 186.77 (+4.17), ESRX: 74.03 (-0.38), CAH: 78.08 (-0.41), UNH: 92.96 (+0.32), CRL: 64.47 (+0.42)
Novartis (NVS) Beats on Q3 Earnings, Revenues; Keeps View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:04PM CDT
Novartis reported core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
AGN: 186.77 (+4.17), LLY: 65.49 (+0.66), GSK: 45.08 (-0.02), NVS: 91.31 (-1.04)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 65.65 (-0.93), VRX: 129.76 (-1.31), ACT: 238.78 (-0.25), AMGN: 158.88 (+1.69), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02), AGN: 186.77 (+4.17), JNJ: 105.56 (+0.77), SHPG: 196.45 (-1.35), MRK: 56.20 (+0.35), INFI: 13.58 (-0.08), ABBV: 59.98 (-0.95), KPTI: 39.81 (+1.78)
McKesson Beats on Q2 Earnings, Revenues; Keeps Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 10:14AM CDT
McKesson Corporation (MCK) reported fiscal second-quarter 2015 (ended Sep 30, 2014) earnings of $2.79 per share, comfortably beating the Zacks Consensus Estimate of $2.74
AGN: 186.77 (+4.17), MCK: 198.45 (-2.75), CAH: 78.08 (-0.41), CRL: 64.47 (+0.42)
Allergan Canada Launches a 3D JUVEDERM(R) Visualization iPad App Powered by ModiFace
Marketwired - Wed Oct 29, 8:02AM CDT
Allergan Canada, in partnership with ModiFace Inc., is delighted to announce the launch of the Juvederm(R) Visualizer 3D iPad application. For the first time, users can create a 3D image of the potential results of Juvederm(R) facial filler showing all angles of their face. This new application enables you to simulate the effects of Juvederm(R) facial filler by creating a 3D image of your face that can be rotated and viewed from all angles. You can then apply over 10 Juvederm(R) treatment effects such as smoothing laugh lines and enhancing cheeks and lips.
AGN: 186.77 (+4.17)
Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:00AM CDT
Gilead Sciences, Inc. reported third-quarter earnings (including stock-based compensation expenses) of $1.79 per share.
AGN: 186.77 (+4.17), GILD: 110.72 (-2.73), MRK: 56.20 (+0.35), ABBV: 59.98 (-0.95)
Pfizer Q3 Earnings Top Estimates Despite Generic Pressure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 3:10PM CDT
Pfizer's (PFE) third quarter earnings and revenues were better-than-expected despite the presence of generic pressure.
AGN: 186.77 (+4.17), BIIB: 315.06 (-2.97), PFE: 29.49 (+0.40), ABBV: 59.98 (-0.95)
Allergan (AGN) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Oct 28, 1:44PM CDT
The following Allergan (AGN) conference call took place on October 27, 2014, 09:00 AM ET. This is a transcript of that earnings call:
AGN: 186.77 (+4.17)
Stock Market News for October 28, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 9:10AM CDT
Benchmarks were little changed on Monday as investors took a breather following last week’s sharp gains
MU: 32.28 (-0.33), VRX: 129.76 (-1.31), NBR: 17.92 (+0.30), HAL: 54.42 (+1.16), XOM: 94.59 (-0.51), BRCD: 10.62 (+0.04), SLB: 97.41 (+0.90), AGN: 186.77 (+4.17), CHK: 21.59 (-0.01), MRK: 56.20 (+0.35), EOG: 93.13 (+1.63), DD: 66.80 (-1.15), PX: 122.61 (-3.09), CVX: 117.14 (+0.01), VZ: 49.83 (-0.13), DOW: 47.38 (-0.60), ECL: 108.16 (-2.45)
Global Postherpetic Neuralgia Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkgchq/postherpetic) has announced the addition of the "Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" report to their offering. Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Postherpetic Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Postherpetic Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Postherpetic Neuralgia. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - NeurogesX, Inc. - Spinifex Pharmaceuticals Pty Limited - Merck & Co., Inc. - UCB S.A. - GlaxoSmithKline plc - Allergan, Inc. - Depomed, Inc. - Daiichi Sankyo Company, Limited - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - University of California, San Francisco - Hopital Ambroise Pare - Shanghai Sixth People's Hospital - Xinhua Hospital - University of Wisconsin Madison - Nucleus Network - Shiraz University of Medical Sciences - George Washington University - Loma Linda University - University of Sao Paulo For more information visit http://www.researchandmarkets.com/research/nk...stherpetic
AGN: 186.77 (+4.17), PFE: 29.49 (+0.40), MRK: 56.20 (+0.35), DEPO: 15.30 (-0.14), GSK: 45.08 (-0.02)
Jim Cramer's Top Stock Picks: CME AGN UNFI SYK
at The Street - Tue Oct 28, 5:00AM CDT
Cramer says Allergan doesn't need a hostile takeover to unlock shareholder value while Stryker is at the top of its game.
AGN: 186.77 (+4.17), CME: 81.83 (+0.50), UNFI: 66.15 (+0.39), SYK: 86.68 (+0.49)
Jim Cramer's 'Mad Money' Recap: How Do You Make Money in a Clueless Market?
at The Street - Mon Oct 27, 6:50PM CDT
In order to truly understand what's going on with the markets you must realize the hedge funds trump everything, Cramer says.
AGN: 186.77 (+4.17), VRX: 129.76 (-1.31), UNFI: 66.15 (+0.39), AZO: 550.04 (+0.32), CMG: 639.86 (-5.99), CFX: 52.52 (+0.17), VSLR: 13.72 (-0.31), IRBT: 34.71 (+0.24), SYK: 86.68 (+0.49)
Allergan lifts outlook
at Investor's Business Daily - Mon Oct 27, 5:49PM CDT
The specialty drugmaker's Q3 EPS ex-items rose 45% to $1.78, beating views by 10 cents. Sales rose 17% to $1.8 bil, slightly above expectations. Allergan (AGN) sees Q4 EPS of $1.80-$1.83, up from $1.35 in '13 and above the $1.76 consensus. Allergan...
AGN: 186.77 (+4.17), VRX: 129.76 (-1.31)
AstraZeneca's Lynparza a Step Closer to European Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 4:41PM CDT
The CHMP gave a positive opinion in favour of approving AstraZeneca's (AZN) Lynparza.
AGN: 186.77 (+4.17), CLVS: 57.24 (-1.81), AZN: 71.53 (+0.10), REGN: 387.70 (-10.19)
Allergan Falls 1.02% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Oct 27, 3:44PM CDT
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $181.19 to a high of $186.80. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $182.77 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 186.77 (+4.17)
Stock Market Today: U.S. Stocks Continue to Party as Oil Nears $70s
at The Street - Mon Oct 27, 3:25PM CDT
Brazil’s runoff presidential election, a Goldman Sachs downgrade across the oil patch and bank stress tests in the European Union did little to impact U.S. stock markets.
AGN: 186.77 (+4.17), PBR: 11.21 (-0.47), VRX: 129.76 (-1.31), RIG: 29.90 (+0.01), NBR: 17.92 (+0.30), MRK: 56.20 (+0.35), XOM: 94.59 (-0.51), CVX: 117.14 (+0.01)
How to Trade the Market's Most-Active Stocks
at The Street - Mon Oct 27, 2:23PM CDT
Here's a look at how to tarde. some of the most active stocks on the market right now.
AGN: 186.77 (+4.17), MU: 32.28 (-0.33), F: 13.91 (-0.25), FNFG: 7.32 (-0.10)
Stock Market Today: Oil Drives Stocks Lower as Goldman Sees Crude at $74 a Barrel
at The Street - Mon Oct 27, 2:03PM CDT
U.S. stocks decline with the energy sector leading markets lower after Goldman Sachs says it expects the price of WTI to trade at $74 a barrel in 2015.
AGN: 186.77 (+4.17), PBR: 11.21 (-0.47), VRX: 129.76 (-1.31), MRK: 56.20 (+0.35), XOM: 94.59 (-0.51), CVX: 117.14 (+0.01)
eVivite.com Continues to Sell VIVITÉ(R) Products After Allergan Announces Its Discontinuation
PRWeb - 2 hrs 17 mins ago
After Allergan's announcement that they will be discontinuing their VIVITÉ(R) skin care product line, online supplier eVivite.com announced their plans to resume sales as long as products are available. As of March 2014 Allergen had already halted production of the products, and they informed retailers that they would only be distributing what had already been produced. The final shipments to suppliers are expected to occur sometime in June.
AGN: 186.77 (+4.17)
San Marcos Dentist, Jeffrey Allred, Certified by Allergan to Provide Botox to Patients Having Dental Problems
PRWeb - Wed Oct 29, 2:11PM CDT
Jeffrey Allred DDS at Allred Dental in San Marcos, CA is now providing therapeutic Botox injections. Botox till recently was known to be used mainly for cosmetic purposes, but now it is used in dentistry as well.
AGN: 186.77 (+4.17)
Express Scripts Reports In-Line Q3 Earnings, Narrows View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:26PM CDT
Express Scripts Holding Company posted third-quarter 2014 earnings per share (excluding special items) of $1.29, in line with the Zacks Consensus Estimate.
AGN: 186.77 (+4.17), ESRX: 74.03 (-0.38), CAH: 78.08 (-0.41), UNH: 92.96 (+0.32), CRL: 64.47 (+0.42)
Novartis (NVS) Beats on Q3 Earnings, Revenues; Keeps View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:04PM CDT
Novartis reported core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
AGN: 186.77 (+4.17), LLY: 65.49 (+0.66), GSK: 45.08 (-0.02), NVS: 91.31 (-1.04)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 65.65 (-0.93), VRX: 129.76 (-1.31), ACT: 238.78 (-0.25), AMGN: 158.88 (+1.69), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02), AGN: 186.77 (+4.17), JNJ: 105.56 (+0.77), SHPG: 196.45 (-1.35), MRK: 56.20 (+0.35), INFI: 13.58 (-0.08), ABBV: 59.98 (-0.95), KPTI: 39.81 (+1.78)
McKesson Beats on Q2 Earnings, Revenues; Keeps Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 10:14AM CDT
McKesson Corporation (MCK) reported fiscal second-quarter 2015 (ended Sep 30, 2014) earnings of $2.79 per share, comfortably beating the Zacks Consensus Estimate of $2.74
AGN: 186.77 (+4.17), MCK: 198.45 (-2.75), CAH: 78.08 (-0.41), CRL: 64.47 (+0.42)
Allergan Canada Launches a 3D JUVEDERM(R) Visualization iPad App Powered by ModiFace
Marketwired - Wed Oct 29, 8:02AM CDT
Allergan Canada, in partnership with ModiFace Inc., is delighted to announce the launch of the Juvederm(R) Visualizer 3D iPad application. For the first time, users can create a 3D image of the potential results of Juvederm(R) facial filler showing all angles of their face. This new application enables you to simulate the effects of Juvederm(R) facial filler by creating a 3D image of your face that can be rotated and viewed from all angles. You can then apply over 10 Juvederm(R) treatment effects such as smoothing laugh lines and enhancing cheeks and lips.
AGN: 186.77 (+4.17)
Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:00AM CDT
Gilead Sciences, Inc. reported third-quarter earnings (including stock-based compensation expenses) of $1.79 per share.
AGN: 186.77 (+4.17), GILD: 110.72 (-2.73), MRK: 56.20 (+0.35), ABBV: 59.98 (-0.95)
Pfizer Q3 Earnings Top Estimates Despite Generic Pressure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 3:10PM CDT
Pfizer's (PFE) third quarter earnings and revenues were better-than-expected despite the presence of generic pressure.
AGN: 186.77 (+4.17), BIIB: 315.06 (-2.97), PFE: 29.49 (+0.40), ABBV: 59.98 (-0.95)
Allergan (AGN) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Oct 28, 1:44PM CDT
The following Allergan (AGN) conference call took place on October 27, 2014, 09:00 AM ET. This is a transcript of that earnings call:
AGN: 186.77 (+4.17)
Stock Market News for October 28, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 9:10AM CDT
Benchmarks were little changed on Monday as investors took a breather following last week’s sharp gains
MU: 32.28 (-0.33), VRX: 129.76 (-1.31), NBR: 17.92 (+0.30), HAL: 54.42 (+1.16), XOM: 94.59 (-0.51), BRCD: 10.62 (+0.04), SLB: 97.41 (+0.90), AGN: 186.77 (+4.17), CHK: 21.59 (-0.01), MRK: 56.20 (+0.35), EOG: 93.13 (+1.63), DD: 66.80 (-1.15), PX: 122.61 (-3.09), CVX: 117.14 (+0.01), VZ: 49.83 (-0.13), DOW: 47.38 (-0.60), ECL: 108.16 (-2.45)
Global Postherpetic Neuralgia Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkgchq/postherpetic) has announced the addition of the "Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" report to their offering. Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Postherpetic Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Postherpetic Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Postherpetic Neuralgia. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - NeurogesX, Inc. - Spinifex Pharmaceuticals Pty Limited - Merck & Co., Inc. - UCB S.A. - GlaxoSmithKline plc - Allergan, Inc. - Depomed, Inc. - Daiichi Sankyo Company, Limited - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - University of California, San Francisco - Hopital Ambroise Pare - Shanghai Sixth People's Hospital - Xinhua Hospital - University of Wisconsin Madison - Nucleus Network - Shiraz University of Medical Sciences - George Washington University - Loma Linda University - University of Sao Paulo For more information visit http://www.researchandmarkets.com/research/nk...stherpetic
AGN: 186.77 (+4.17), PFE: 29.49 (+0.40), MRK: 56.20 (+0.35), DEPO: 15.30 (-0.14), GSK: 45.08 (-0.02)
Jim Cramer's Top Stock Picks: CME AGN UNFI SYK
at The Street - Tue Oct 28, 5:00AM CDT
Cramer says Allergan doesn't need a hostile takeover to unlock shareholder value while Stryker is at the top of its game.
AGN: 186.77 (+4.17), CME: 81.83 (+0.50), UNFI: 66.15 (+0.39), SYK: 86.68 (+0.49)
Jim Cramer's 'Mad Money' Recap: How Do You Make Money in a Clueless Market?
at The Street - Mon Oct 27, 6:50PM CDT
In order to truly understand what's going on with the markets you must realize the hedge funds trump everything, Cramer says.
AGN: 186.77 (+4.17), VRX: 129.76 (-1.31), UNFI: 66.15 (+0.39), AZO: 550.04 (+0.32), CMG: 639.86 (-5.99), CFX: 52.52 (+0.17), VSLR: 13.72 (-0.31), IRBT: 34.71 (+0.24), SYK: 86.68 (+0.49)
Allergan lifts outlook
at Investor's Business Daily - Mon Oct 27, 5:49PM CDT
The specialty drugmaker's Q3 EPS ex-items rose 45% to $1.78, beating views by 10 cents. Sales rose 17% to $1.8 bil, slightly above expectations. Allergan (AGN) sees Q4 EPS of $1.80-$1.83, up from $1.35 in '13 and above the $1.76 consensus. Allergan...
AGN: 186.77 (+4.17), VRX: 129.76 (-1.31)
AstraZeneca's Lynparza a Step Closer to European Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 4:41PM CDT
The CHMP gave a positive opinion in favour of approving AstraZeneca's (AZN) Lynparza.
AGN: 186.77 (+4.17), CLVS: 57.24 (-1.81), AZN: 71.53 (+0.10), REGN: 387.70 (-10.19)
Allergan Falls 1.02% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Oct 27, 3:44PM CDT
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $181.19 to a high of $186.80. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $182.77 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 186.77 (+4.17)
Stock Market Today: U.S. Stocks Continue to Party as Oil Nears $70s
at The Street - Mon Oct 27, 3:25PM CDT
Brazil’s runoff presidential election, a Goldman Sachs downgrade across the oil patch and bank stress tests in the European Union did little to impact U.S. stock markets.
AGN: 186.77 (+4.17), PBR: 11.21 (-0.47), VRX: 129.76 (-1.31), RIG: 29.90 (+0.01), NBR: 17.92 (+0.30), MRK: 56.20 (+0.35), XOM: 94.59 (-0.51), CVX: 117.14 (+0.01)
How to Trade the Market's Most-Active Stocks
at The Street - Mon Oct 27, 2:23PM CDT
Here's a look at how to tarde. some of the most active stocks on the market right now.
AGN: 186.77 (+4.17), MU: 32.28 (-0.33), F: 13.91 (-0.25), FNFG: 7.32 (-0.10)
Stock Market Today: Oil Drives Stocks Lower as Goldman Sees Crude at $74 a Barrel
at The Street - Mon Oct 27, 2:03PM CDT
U.S. stocks decline with the energy sector leading markets lower after Goldman Sachs says it expects the price of WTI to trade at $74 a barrel in 2015.
AGN: 186.77 (+4.17), PBR: 11.21 (-0.47), VRX: 129.76 (-1.31), MRK: 56.20 (+0.35), XOM: 94.59 (-0.51), CVX: 117.14 (+0.01)
